F6300
Flumazenil
>99% (HPLC), solid, benzodiazepine receptor antagonist
동의어(들):
Ro 15-1788, Ro15-1788
조직 및 계약 가격을 보려면 로그인를 클릭합니다.
크기 선택
보기 변경
제품정보 (DICE 배송 시 비용 별도)
실험식(Hill 표기법):
C15H14FN3O3
CAS 번호:
Molecular Weight:
303.29
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77
MDL number:
제품 이름
Flumazenil, >99% (HPLC), solid
Quality Level
assay
>99% (HPLC)
form
solid
color
white
originator
Roche
storage temp.
2-8°C
SMILES string
CCOC(=O)c1ncn-2c1CN(C)C(=O)c3cc(F)ccc-23
InChI
1S/C15H14FN3O3/c1-3-22-15(21)13-12-7-18(2)14(20)10-6-9(16)4-5-11(10)19(12)8-17-13/h4-6,8H,3,7H2,1-2H3
InChI key
OFBIFZUFASYYRE-UHFFFAOYSA-N
Gene Information
General description
Flumazenil reverses sedative and hypnotic effects of benzodiazepines. It is used to increase acquisition, enhance retention and treat amnesia in mice.
Biochem/physiol Actions
Highly specific benzodiazepine receptor antagonist.
Features and Benefits
This compound is a featured product for Neuroscience research. Click here to discover more featured Neuroscience products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
This compound is featured on the GABAA Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Roche. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
저장 등급
11 - Combustible Solids
wgk
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
문서
신경과학을 위한 생체 활성 저분자
DISCOVER Bioactive Small Molecules for Neuroscience
Effect of flumazenil on memory retrieval determined by trial-to-criteria inhibitory avoidance method in mice
Raut SB, et al.
Journal of Pharmacology & Pharmacotherapeutics, 7(1), 24-24 (2016)
N W Duncan et al.
Neuroscience, 235, 226-231 (2013-02-06)
Voxel based morphometry (VBM) is a widely used technique for studying the structure of the brain. Direct comparisons between the results obtained using VBM and the underlying histology are limited, however. To circumvent the problems inherent in comparing VBM data
Donna L Seger
Journal of toxicology. Clinical toxicology, 42(2), 209-216 (2004-06-25)
Flumazenil is frequently administered to the poisoned patient. Seizures may be precipitated and resedation may occur in patients who awakened following flumazenil administration. Seizures may increase morbidity and mortality of the overdose. Benefit:Risk ratio of administering flumazenil should be determined